Clinical trial NCT01318941: Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
Official title: LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Wet Age Related Macular Degeneration
Diabetic Macular Edema
Retinal Vein Occlusion
Keywords: Ophthalmology, age-related macular degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, ranibizumab
Ophthalmology
Age-related macular degeneration
Diabetic Macular Edema
Retinal Vein Occlusion
LUMINOUS
Ranibizumab
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2011-03-21
Enrollment: 30490
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatient ophthalmology Clinics

Brief summary: This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.


Eligibility criteria: Inclusion Criteria:

* Adult patients, within age limits as defined by local regulations and local product label, who have previously been treated with, who are currently being treated with or initiating treatment with ranibizumab for any approved indication included in the local product label
* Willing and able to provide informed written consent personally or by legal proxy

Exclusion Criteria:

* Simultaneous participation in a study that includes administration of any investigational drug or procedure
* Systemic or ocular treatment with any VEGF inhibitor other than ranibizumab in the 90 days prior to enrollment
* Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Mean Visual Acuity (VA) and mean change in VA
timeFrame: 3,6, and 12 months from the baseline visit, and annually thereafter
measure: Incidence rate, relationship and severity of treatment emergent ocular and non-ocular adverse events
timeFrame: Defined time periods during study duration from FPFV until 30 days after LPLV
measure: Mean visual acuity at quarterly intervals for the primary treated eye set
timeFrame: Quarterly intervals from baseline visit during study duration (5 years)
Secondary outcomes:
measure: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: From the time the patient signed the informed consent until 30 days after study discontinuation
measure: Number of ranibizumab injections administered per patient, per eye, and per person-year
timeFrame: annually
measure: "National Eye Institute Visual Functioning Questionnaire-25" change from baseline
timeFrame: annually
measure: Overall number of ranibizumab injections, number of visits, time interval between injections, duration of treatment, number of re-treatment, and reasons for treatment termination
timeFrame: Over time during study duration (5 years)
measure: Change from baseline in National Eye Institute Visual Function Questionnaire 25 composite and sub-scale scores
timeFrame: Over time during study duration (5 years)
Other outcomes:
Locations:
city: Lanus
country: Argentina
facility: Novartis Investigative Site
state: Buenos Aires
city: Mar del Plata
country: Argentina
facility: Novartis Investigative Site
state: Buenos Aires
city: Rosario
country: Argentina
facility: Novartis Investigative Site
state: Santa Fe
city: Buenos Aires
country: Argentina
facility: Novartis Investigative Site
city: Buenos Aires
country: Argentina
facility: Novartis Investigative Site
city: Buenos Aires
country: Argentina
facility: Novartis Investigative Site
city: Buenos Aires
country: Argentina
facility: Novartis Investigative Site
city: Caballito
country: Argentina
facility: Novartis Investigative Site
city: Ciudad de Buenos Aires,
country: Argentina
facility: Novartis Investigative Site
city: Concepción del Uruguay
country: Argentina
facility: Novartis Investigative Site
city: Córdoba
country: Argentina
facility: Novartis Investigative Site
city: Guaymallén, Mendoza
country: Argentina
facility: Novartis Investigative Site
city: La Plata
country: Argentina
facility: Novartis Investigative Site
city: Rosario
country: Argentina
facility: Novartis Investigative Site
city: San Martin, Buenos Aires
country: Argentina
facility: Novartis Investigative Site
city: Santa Fe
country: Argentina
facility: Novartis Investigative Site
city: Santa Fe
country: Argentina
facility: Novartis Investigative Site
city: Chatswood
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Forster
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Kogarah
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Liverpool
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: North Ryde
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Parramatta
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Strathfield
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Sydney
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Sydney
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Westmead
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Brisbane
country: Australia
facility: Novartis Investigative Site
state: Queensland
city: South Brisbane
country: Australia
facility: Novartis Investigative Site
state: Queensland
city: Southport
country: Australia
facility: Novartis Investigative Site
state: Queensland
city: Adelaide
country: Australia
facility: Novartis Investigative Site
state: South Australia
city: North Adelaide
country: Australia
facility: Novartis Investigative Site
state: South Australia
city: Hobart
country: Australia
facility: Novartis Investigative Site
state: Tasmania
city: South Launceston
country: Australia
facility: Novartis Investigative Site
state: Tasmania
city: East Melbourne
country: Australia
facility: Novartis Investigative Site
state: Victoria
city: Geelong
country: Australia
facility: Novartis Investigative Site
state: Victoria
city: Glen Waverley
country: Australia
facility: Novartis Investigative Site
state: Victoria
city: Oakleigh
country: Australia
facility: Novartis Investigative Site
state: Victoria
city: Linz
country: Austria
facility: Novartis Investigative Site
city: Vienna
country: Austria
facility: Novartis Investigative Site
city: Aalst
country: Belgium
facility: Novartis Investigative Site
city: Aarschot
country: Belgium
facility: Novartis Investigative Site
city: Bonheiden
country: Belgium
facility: Novartis Investigative Site
city: Bruxelles
country: Belgium
facility: Novartis Investigative Site
city: Dinant
country: Belgium
facility: Novartis Investigative Site
city: Edegem
country: Belgium
facility: Novartis Investigative Site
city: Gent
country: Belgium
facility: Novartis Investigative Site
city: Hasselt
country: Belgium
facility: Novartis Investigative Site
city: Leuven
country: Belgium
facility: Novartis Investigative Site
city: Mouscron
country: Belgium
facility: Novartis Investigative Site
city: Namur
country: Belgium
facility: Novartis Investigative Site
city: Nivelles
country: Belgium
facility: Novartis Investigative Site
city: Reet
country: Belgium
facility: Novartis Investigative Site
city: Yvoir
country: Belgium
facility: Novartis Investigative Site
city: Zottegem
country: Belgium
facility: Novartis Investigative Site
city: Goiania
country: Brazil
facility: Novartis Investigative Site
state: GO
city: Belo Horizonte
country: Brazil
facility: Novartis Investigative Site
state: MG
city: Rio de Janeiro
country: Brazil
facility: Novartis Investigative Site
state: RJ
city: Porto Alegre
country: Brazil
facility: Novartis Investigative Site
state: RS
city: Campinas
country: Brazil
facility: Novartis Investigative Site
state: SP
city: São Paulo
country: Brazil
facility: Novartis Investigative Site
state: SP
city: Calgary
country: Canada
facility: Novartis Investigative Site
state: Alberta
city: Victoria
country: Canada
facility: Novartis Investigative Site
state: British Columbia
city: Miramichi
country: Canada
facility: Novartis Investigative Site
state: New Brunswick
city: Halifax
country: Canada
facility: Novartis Investigative Site
state: Nova Scotia
city: Brampton
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: Downsview
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: East Brockville
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: London
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: Ottawa
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: Ottawa
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: Scarborough
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: Toronto
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: Vaughan
country: Canada
facility: Novartis Investigative Site
state: Ontario
city: Boisbriand
country: Canada
facility: Novartis Investigative Site
state: Quebec
city: Barrie
country: Canada
facility: Novartis Investigative Site
city: Drummondville
country: Canada
facility: Novartis Investigative Site
city: Hamilton
country: Canada
facility: Novartis Investigative Site
city: Ontario
country: Canada
facility: Novartis Investigative Site
city: Calama
country: Chile
facility: Novartis Investigative Site
city: Beijing
country: China
facility: Novartis Investigative Site
state: Beijing
city: Beijing
country: China
facility: Novartis Investigative Site
state: Beijing
city: Beijing
country: China
facility: Novartis Investigative Site
state: Beijing
city: Guangzhou
country: China
facility: Novartis Investigative Site
state: Guangdong
city: Guiyang
country: China
facility: Novartis Investigative Site
state: Guizhou
city: Wuhan
country: China
facility: Novartis Investigative Site
state: Hubei
city: Jinan
country: China
facility: Novartis Investigative Site
state: Shandong
city: Tianjin
country: China
facility: Novartis Investigative Site
state: Tianjin
city: Kunming City
country: China
facility: Novartis Investigative Site
state: Yunnan
city: Beijing
country: China
facility: Novartis Investigative Site
city: Beijing
country: China
facility: Novartis Investigative Site
city: Beijing
country: China
facility: Novartis Investigative Site
city: Changchun City
country: China
facility: Novartis Investigative Site
city: Chongqing
country: China
facility: Novartis Investigative Site
city: Fujian
country: China
facility: Novartis Investigative Site
city: Shanghai
country: China
facility: Novartis Investigative Site
city: Shanghai
country: China
facility: Novartis Investigative Site
city: Shanghai
country: China
facility: Novartis Investigative Site
city: Wulumuqi City
country: China
facility: Novartis Investigative Site
city: Barranquilla
country: Colombia
facility: Novartis Investigative Site
state: Atlantico
city: Armenia
country: Colombia
facility: Novartis Investigative Site
state: Quindío
city: Bogota
country: Colombia
facility: Novartis Investigative Site
city: Bogotá
country: Colombia
facility: Novartis Investigative Site
city: Cali
country: Colombia
facility: Novartis Investigative Site
city: Yopal
country: Colombia
facility: Novartis Investigative Site
city: San Jose
country: Costa Rica
facility: Novartis Investigative Site
city: Brno - Bohunice
country: Czech Republic
facility: Novartis Investigative Site
city: Hradec Kralove
country: Czech Republic
facility: Novartis Investigative Site
city: Olomouc
country: Czech Republic
facility: Novartis Investigative Site
city: Ostrava-Poruba
country: Czech Republic
facility: Novartis Investigative Site
city: Plzen
country: Czech Republic
facility: Novartis Investigative Site
city: Praha 10
country: Czech Republic
facility: Novartis Investigative Site
city: Praha
country: Czech Republic
facility: Novartis Investigative Site
city: Praha
country: Czech Republic
facility: Novartis Investigative Site
city: Ustri nad Labem
country: Czech Republic
facility: Novartis Investigative Site
city: Santo Domingo
country: Dominican Republic
facility: Novartis Investigative Site
state: Republica Dominicana
city: Ciudadela Kennedy
country: Ecuador
facility: Novartis Investigative Site
state: Guayaquil
city: Cairo
country: Egypt
facility: Novartis Investigative Site
city: Giza
country: Egypt
facility: Novartis Investigative Site
city: Bordeaux
country: France
facility: Novartis Investigative Site
city: Creteil
country: France
facility: Novartis Investigative Site
city: Dijon
country: France
facility: Novartis Investigative Site
city: Lyon CEDEX 04
country: France
facility: Novartis Investigative Site
city: Melun
country: France
facility: Novartis Investigative Site
city: Montargis
country: France
facility: Novartis Investigative Site
city: Montauban
country: France
facility: Novartis Investigative Site
city: Nantes Cedex 1
country: France
facility: Novartis Investigative Site
city: Nice
country: France
facility: Novartis Investigative Site
city: Paris cedex 10
country: France
facility: Novartis Investigative Site
city: Paris Cedex 19
country: France
facility: Novartis Investigative Site
city: Paris
country: France
facility: Novartis Investigative Site
city: Paris
country: France
facility: Novartis Investigative Site
city: Poitiers
country: France
facility: Novartis Investigative Site
city: Reims
country: France
facility: Novartis Investigative Site
city: Toulouse Cedex 9
country: France
facility: Novartis Investigative Site
city: Vannes
country: France
facility: Novartis Investigative Site
city: Augsburg
country: Germany
facility: Novartis Investigative Site
city: Berlin
country: Germany
facility: Novartis Investigative Site
city: Berlin
country: Germany
facility: Novartis Investigative Site
city: Bonn
country: Germany
facility: Novartis Investigative Site
city: Dannenberg
country: Germany
facility: Novartis Investigative Site
city: Hamburg
country: Germany
facility: Novartis Investigative Site
city: Ingolstadt
country: Germany
facility: Novartis Investigative Site
city: Koeln
country: Germany
facility: Novartis Investigative Site
city: Luedenscheid
country: Germany
facility: Novartis Investigative Site
city: Muenster
country: Germany
facility: Novartis Investigative Site
city: Muenster
country: Germany
facility: Novartis Investigative Site
city: Neu-Ulm
country: Germany
facility: Novartis Investigative Site
city: Osnabrück
country: Germany
facility: Novartis Investigative Site
city: Regensburg
country: Germany
facility: Novartis Investigative Site
city: Rothenburg
country: Germany
facility: Novartis Investigative Site
city: Schriesheim
country: Germany
facility: Novartis Investigative Site
city: Tuebingen
country: Germany
facility: Novartis Investigative Site
city: Tönisvorst
country: Germany
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
state: GR
city: Heraklion - Crete
country: Greece
facility: Novartis Investigative Site
state: GR
city: Larissa
country: Greece
facility: Novartis Investigative Site
state: GR
city: Patra - RIO
country: Greece
facility: Novartis Investigative Site
state: GR
city: Rethymno
country: Greece
facility: Novartis Investigative Site
state: GR
city: Thessaloniki
country: Greece
facility: Novartis Investigative Site
state: GR
city: Alexandroupolis
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Lamia, Phthiotis
country: Greece
facility: Novartis Investigative Site
city: Guatemala City
country: Guatemala
facility: Novartis Investigative Site
city: Kowloon
country: Hong Kong
facility: Novartis Investigative Site
city: Budapest
country: Hungary
facility: Novartis Investigative Site
city: Budapest
country: Hungary
facility: Novartis Investigative Site
city: Debrecen
country: Hungary
facility: Novartis Investigative Site
city: Pecs
country: Hungary
facility: Novartis Investigative Site
city: Szeged
country: Hungary
facility: Novartis Investigative Site
city: Patia
country: India
facility: Novartis Investigative Site
state: Bhudaneswar
city: Chennai
country: India
facility: Novartis Investigative Site
state: Tamil Nadu
city: Coimbatore
country: India
facility: Novartis Investigative Site
state: Tamil Nadu
city: Hyderabad
country: India
facility: Novartis Investigative Site
state: Telangana
city: Ahmedabad
country: India
facility: Novartis Investigative Site
city: New Delhi
country: India
facility: Novartis Investigative Site
city: Dublin 7
country: Ireland
facility: Novartis Investigative Site
city: Dublin
country: Ireland
facility: Novartis Investigative Site
city: Waterford
country: Ireland
facility: Novartis Investigative Site
city: Haifa
country: Israel
facility: Novartis Investigative Site
city: Petach Tikva
country: Israel
facility: Novartis Investigative Site
city: Tel Aviv
country: Israel
facility: Novartis Investigative Site
city: Acquaviva delle Fonti
country: Italy
facility: Novartis Investigative Site
state: BA
city: Cagliari
country: Italy
facility: Novartis Investigative Site
state: CA
city: Genova
country: Italy
facility: Novartis Investigative Site
state: GE
city: Alessandria
country: Italy
facility: Novartis Investigative Site
city: Belluno
country: Italy
facility: Novartis Investigative Site
city: Brescia
country: Italy
facility: Novartis Investigative Site
city: Pisa
country: Italy
facility: Novartis Investigative Site
city: Reggio Calabria
country: Italy
facility: Novartis Investigative Site
city: Roma
country: Italy
facility: Novartis Investigative Site
city: Roma
country: Italy
facility: Novartis Investigative Site
city: Nagakute-city
country: Japan
facility: Novartis Investigative Site
state: Aichi
city: Nagoya-city
country: Japan
facility: Novartis Investigative Site
state: Aichi
city: Nagoya-city
country: Japan
facility: Novartis Investigative Site
state: Aichi
city: Nagoya-City
country: Japan
facility: Novartis Investigative Site
state: Aichi
city: Toyoake-city
country: Japan
facility: Novartis Investigative Site
state: Aichi
city: Sakura
country: Japan
facility: Novartis Investigative Site
state: Chiba
city: Matsuyama
country: Japan
facility: Novartis Investigative Site
state: Ehime
city: Yoshida-gun
country: Japan
facility: Novartis Investigative Site
state: Fukui
city: Fukuoka-city
country: Japan
facility: Novartis Investigative Site
state: Fukuoka
city: Fukuoka-city
country: Japan
facility: Novartis Investigative Site
state: Fukuoka
city: Kitakyushu-city
country: Japan
facility: Novartis Investigative Site
state: Fukuoka
city: Fukushima-city
country: Japan
facility: Novartis Investigative Site
state: Fukushima
city: Maebashi-city
country: Japan
facility: Novartis Investigative Site
state: Gunma
city: Hiroshima-city
country: Japan
facility: Novartis Investigative Site
state: Hiroshima
city: Sapporo-city
country: Japan
facility: Novartis Investigative Site
state: Hokkaido
city: Sapporo-city
country: Japan
facility: Novartis Investigative Site
state: Hokkido
city: Amagasaki-city
country: Japan
facility: Novartis Investigative Site
state: Hyogo
city: Kobe
country: Japan
facility: Novartis Investigative Site
state: Hyogo
city: Nishinomiya
country: Japan
facility: Novartis Investigative Site
state: Hyogo
city: Inashiki-gun
country: Japan
facility: Novartis Investigative Site
state: Ibaraki
city: Tsukuba-city
country: Japan
facility: Novartis Investigative Site
state: Ibaraki
city: Kanazawa-city
country: Japan
facility: Novartis Investigative Site
state: Ishikawa
city: Kita-gun
country: Japan
facility: Novartis Investigative Site
state: Kagawa
city: Ashigarakami-gun
country: Japan
facility: Novartis Investigative Site
state: Kanagawa
city: Yokohama-city
country: Japan
facility: Novartis Investigative Site
state: Kanagawa
city: Yokosuka-city
country: Japan
facility: Novartis Investigative Site
state: Kanagawa
city: Yokohama
country: Japan
facility: Novartis Investigative Site
state: Kangawa
city: Kyoto-city
country: Japan
facility: Novartis Investigative Site
state: Kyoto
city: Tsu-city
country: Japan
facility: Novartis Investigative Site
state: Mie
city: Sendai
country: Japan
facility: Novartis Investigative Site
state: Miyagi
city: Miyakonojo-City
country: Japan
facility: Novartis Investigative Site
state: Miyazakiken
city: Miyazaki-city
country: Japan
facility: Novartis Investigative Site
state: Miyazaki
city: Suwa
country: Japan
facility: Novartis Investigative Site
state: Nagano
city: Nagasaki-city
country: Japan
facility: Novartis Investigative Site
state: Nagasaki
city: Kashihara-city
country: Japan
facility: Novartis Investigative Site
state: Nara
city: Hirakata-city
country: Japan
facility: Novartis Investigative Site
state: Osaka
city: Osaka-city
country: Japan
facility: Novartis Investigative Site
state: Osaka
city: OsakaSayama
country: Japan
facility: Novartis Investigative Site
state: Osaka
city: Saitama-city
country: Japan
facility: Novartis Investigative Site
state: Saitama
city: Hamamatsu-city
country: Japan
facility: Novartis Investigative Site
state: Shizuoka
city: Izunokuni
country: Japan
facility: Novartis Investigative Site
state: Shizuoka
city: Shimotsuka-gun
country: Japan
facility: Novartis Investigative Site
state: Tochigi
city: Tokushima-city
country: Japan
facility: Novartis Investigative Site
state: Tokushima
city: Bunkyo-ku
country: Japan
facility: Novartis Investigative Site
state: Tokyo
city: Chiyoda-ku
country: Japan
facility: Novartis Investigative Site
state: Tokyo
city: Mitaka-city
country: Japan
facility: Novartis Investigative Site
state: Tokyo
city: Nerima-ku
country: Japan
facility: Novartis Investigative Site
state: Tokyo
city: Shinjuku-ku
country: Japan
facility: Novartis Investigative Site
state: Tokyo
city: Shinjuku-ku
country: Japan
facility: Novartis Investigative Site
state: Tokyo
city: Urayasu
country: Japan
facility: Novartis Investigative Site
state: Tokyo
city: Imizu-shi
country: Japan
facility: Novartis Investigative Site
state: Toyama
city: Chuo-city
country: Japan
facility: Novartis Investigative Site
state: Yamanashi
city: Akita
country: Japan
facility: Novartis Investigative Site
city: Aomori
country: Japan
facility: Novartis Investigative Site
city: Chiyoda-ku
country: Japan
facility: Novartis Investigative Site
city: Ehime
country: Japan
facility: Novartis Investigative Site
city: Gifu
country: Japan
facility: Novartis Investigative Site
city: Hamamatsu-shi
country: Japan
facility: Novartis Investigative Site
city: Hokkaido
country: Japan
facility: Novartis Investigative Site
city: Hokkaido
country: Japan
facility: Novartis Investigative Site
city: Hyogo
country: Japan
facility: Novartis Investigative Site
city: Ishikawa
country: Japan
facility: Novartis Investigative Site
city: Kagoshima
country: Japan
facility: Novartis Investigative Site
city: Kagoshima
country: Japan
facility: Novartis Investigative Site
city: Kakogawa-shi
country: Japan
facility: Novartis Investigative Site
city: Kanagawa
country: Japan
facility: Novartis Investigative Site
city: Kawasaki-shi
country: Japan
facility: Novartis Investigative Site
city: Kitami-shi
country: Japan
facility: Novartis Investigative Site
city: Koriyama-shi
country: Japan
facility: Novartis Investigative Site
city: Kouchi
country: Japan
facility: Novartis Investigative Site
city: Kyoto-shi
country: Japan
facility: Novartis Investigative Site
city: Miyagi
country: Japan
facility: Novartis Investigative Site
city: Nagano
country: Japan
facility: Novartis Investigative Site
city: Nagasaki-shi
country: Japan
facility: Novartis Investigative Site
city: Nantan-shi
country: Japan
facility: Novartis Investigative Site
city: Osaka
country: Japan
facility: Novartis Investigative Site
city: Otsu-shi
country: Japan
facility: Novartis Investigative Site
city: Saitama-ken
country: Japan
facility: Novartis Investigative Site
city: Saitama
country: Japan
facility: Novartis Investigative Site
city: Sanjo-shi
country: Japan
facility: Novartis Investigative Site
city: Shizuoka-shi
country: Japan
facility: Novartis Investigative Site
city: Shizuoka
country: Japan
facility: Novartis Investigative Site
city: Shunan-shi
country: Japan
facility: Novartis Investigative Site
city: Tochigi
country: Japan
facility: Novartis Investigative Site
city: Tokyo
country: Japan
facility: Novartis Investigative Site
city: Tokyo
country: Japan
facility: Novartis Investigative Site
city: Toyama
country: Japan
facility: Novartis Investigative Site
city: Toyohashi-shi
country: Japan
facility: Novartis Investigative Site
city: Wakayama
country: Japan
facility: Novartis Investigative Site
city: Yamagata
country: Japan
facility: Novartis Investigative Site
city: Yamagata
country: Japan
facility: Novartis Investigative Site
city: Suwon
country: Korea, Republic of
facility: Novartis Investigative Site
state: Gyeonggi-do
city: Seongnam
country: Korea, Republic of
facility: Novartis Investigative Site
state: Gyeonggi
city: Seoul
country: Korea, Republic of
facility: Novartis Investigative Site
state: Korea
city: Seoul
country: Korea, Republic of
facility: Novartis Investigative Site
state: Korea
city: Busan
country: Korea, Republic of
facility: Novartis Investigative Site
city: Daegu
country: Korea, Republic of
facility: Novartis Investigative Site
city: Pusan
country: Korea, Republic of
facility: Novartis Investigative Site
city: Seoul
country: Korea, Republic of
facility: Novartis Investigative Site
city: Seoul
country: Korea, Republic of
facility: Novartis Investigative Site
city: Seoul
country: Korea, Republic of
facility: Novartis Investigative Site
city: Seoul
country: Korea, Republic of
facility: Novartis Investigative Site
city: Seoul
country: Korea, Republic of
facility: Novartis Investigative Site
city: Taegu
country: Korea, Republic of
facility: Novartis Investigative Site
city: Batu Caves
country: Malaysia
facility: Novartis Investigative Site
state: Selangor
city: Kuala Lumpur
country: Malaysia
facility: Novartis Investigative Site
city: Kuala Lumpur
country: Malaysia
facility: Novartis Investigative Site
city: Kuala Lumpur
country: Malaysia
facility: Novartis Investigative Site
city: Col. Lomas de Chapultepec
country: Mexico
facility: Novartis Investigative Site
state: CP
city: Ciudad De Mexico
country: Mexico
facility: Novartis Investigative Site
state: Distrito Federal
city: Ciudad De Mexico
country: Mexico
facility: Novartis Investigative Site
state: Distrito Federal
city: Monterray
country: Mexico
facility: Novartis Investigative Site
state: Nuevo León
city: Monterrey
country: Mexico
facility: Novartis Investigative Site
state: Nuevo León
city: Mérida
country: Mexico
facility: Novartis Investigative Site
state: Yucatán
city: Almere
country: Netherlands
facility: Novartis Investigative Site
city: Amsterdam
country: Netherlands
facility: Novartis Investigative Site
city: Tilburg
country: Netherlands
facility: Novartis Investigative Site
city: Panama City
country: Panama
facility: Novartis Investigative Site
state: Panamá
city: Panama
country: Panama
facility: Novartis Investigative Site
state: Panamá
city: San Borja
country: Peru
facility: Novartis Investigative Site
state: Lima
city: San Isidro
country: Peru
facility: Novartis Investigative Site
state: Lima
city: Lima
country: Peru
facility: Novartis Investigative Site
city: Bydgoszcz
country: Poland
facility: Novartis Investigative Site
city: Chojnice
country: Poland
facility: Novartis Investigative Site
city: Chorzow
country: Poland
facility: Novartis Investigative Site
city: Gdansk
country: Poland
facility: Novartis Investigative Site
city: Gda¿sk
country: Poland
facility: Novartis Investigative Site
city: Kalisz
country: Poland
facility: Novartis Investigative Site
city: Kielce
country: Poland
facility: Novartis Investigative Site
city: Krakow
country: Poland
facility: Novartis Investigative Site
city: Lodz
country: Poland
facility: Novartis Investigative Site
city: Olsztyn
country: Poland
facility: Novartis Investigative Site
city: Poznan
country: Poland
facility: Novartis Investigative Site
city: Walbrzych
country: Poland
facility: Novartis Investigative Site
city: Warszawa
country: Poland
facility: Novartis Investigative Site
city: Warszawa
country: Poland
facility: Novartis Investigative Site
city: Wolomin
country: Poland
facility: Novartis Investigative Site
city: Aveiro
country: Portugal
facility: Novartis Investigative Site
city: Coimbra
country: Portugal
facility: Novartis Investigative Site
city: Coimbra
country: Portugal
facility: Novartis Investigative Site
city: Leiria
country: Portugal
facility: Novartis Investigative Site
city: Lisboa
country: Portugal
facility: Novartis Investigative Site
city: Matosinhos
country: Portugal
facility: Novartis Investigative Site
city: Santa Maria Da Feira
country: Portugal
facility: Novartis Investigative Site
city: Cheboksary
country: Russian Federation
facility: Novartis Investigative Site
city: Chelyabinsk
country: Russian Federation
facility: Novartis Investigative Site
city: Chita
country: Russian Federation
facility: Novartis Investigative Site
city: Irkutsk
country: Russian Federation
facility: Novartis Investigative Site
city: Kazan
country: Russian Federation
facility: Novartis Investigative Site
city: Khabarovsk
country: Russian Federation
facility: Novartis Investigative Site
city: Krasnodar
country: Russian Federation
facility: Novartis Investigative Site
city: Moscow
country: Russian Federation
facility: Novartis Investigative Site
city: Moscow
country: Russian Federation
facility: Novartis Investigative Site
city: Moscow
country: Russian Federation
facility: Novartis Investigative Site
city: Novosibirsk
country: Russian Federation
facility: Novartis Investigative Site
city: Penza
country: Russian Federation
facility: Novartis Investigative Site
city: Saint Petersburg
country: Russian Federation
facility: Novartis Investigative Site
city: Samara
country: Russian Federation
facility: Novartis Investigative Site
city: Saratov
country: Russian Federation
facility: Novartis Investigative Site
city: Surgut
country: Russian Federation
facility: Novartis Investigative Site
city: Tambov
country: Russian Federation
facility: Novartis Investigative Site
city: Tyumen
country: Russian Federation
facility: Novartis Investigative Site
city: Ufa
country: Russian Federation
facility: Novartis Investigative Site
city: Yakutsk
country: Russian Federation
facility: Novartis Investigative Site
city: Riyadh
country: Saudi Arabia
facility: Novartis Investigative Site
city: Riyadh
country: Saudi Arabia
facility: Novartis Investigative Site
city: Riyadh
country: Saudi Arabia
facility: Novartis Investigative Site
city: Singapore
country: Singapore
facility: Novartis Investigative Site
city: Singapore
country: Singapore
facility: Novartis Investigative Site
city: Singapore
country: Singapore
facility: Novartis Investigative Site
city: Banksa Bystrica
country: Slovakia
facility: Novartis Investigative Site
state: Slovak Republic
city: Trebisov
country: Slovakia
facility: Novartis Investigative Site
state: Slovak Republic
city: Bratislava
country: Slovakia
facility: Novartis Investigative Site
city: Bratislava
country: Slovakia
facility: Novartis Investigative Site
city: Bratislava
country: Slovakia
facility: Novartis Investigative Site
city: Ljubljana
country: Slovakia
facility: Novartis Investigative Site
city: Nove Zamky
country: Slovakia
facility: Novartis Investigative Site
city: Poprad
country: Slovakia
facility: Novartis Investigative Site
city: Ruzomberok
country: Slovakia
facility: Novartis Investigative Site
city: Trencin
country: Slovakia
facility: Novartis Investigative Site
city: Zilina
country: Slovakia
facility: Novartis Investigative Site
city: Zvolen
country: Slovakia
facility: Novartis Investigative Site
city: Celje
country: Slovenia
facility: Novartis Investigative Site
city: Ljubljana
country: Slovenia
facility: Novartis Investigative Site
city: Maribor
country: Slovenia
facility: Novartis Investigative Site
city: Novo Mesto
country: Slovenia
facility: Novartis Investigative Site
city: Malaga
country: Spain
facility: Novartis Investigative Site
state: Andalucia
city: Leon
country: Spain
facility: Novartis Investigative Site
state: Castilla y Leon
city: Salamanca
country: Spain
facility: Novartis Investigative Site
state: Castilla y Leon
city: Valladolid
country: Spain
facility: Novartis Investigative Site
state: Castilla y Leon
city: Sant Cugat
country: Spain
facility: Novartis Investigative Site
state: Catalunya
city: Tarragona
country: Spain
facility: Novartis Investigative Site
state: Catalunya
city: Barcelona
country: Spain
facility: Novartis Investigative Site
state: Cataluña
city: Valencia
country: Spain
facility: Novartis Investigative Site
state: Comunidad Valenciana
city: Valencia
country: Spain
facility: Novartis Investigative Site
state: Comunidad Valenciana
city: Lugo
country: Spain
facility: Novartis Investigative Site
state: Galicia
city: Logroño
country: Spain
facility: Novartis Investigative Site
state: Hospital La Rioja provincia
city: Barcelona
country: Spain
facility: Novartis Investigative Site
city: Burgos
country: Spain
facility: Novartis Investigative Site
city: Granollers
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Murcia
country: Spain
facility: Novartis Investigative Site
city: Zaragoza
country: Spain
facility: Novartis Investigative Site
city: Altindag / Ankara
country: Turkey
facility: Novartis Investigative Site
city: Ankara
country: Turkey
facility: Novartis Investigative Site
city: Ankara
country: Turkey
facility: Novartis Investigative Site
city: Mecidiyekoy/Istanbul
country: Turkey
facility: Novartis Investigative Site
city: Dnipropetrovsk
country: Ukraine
facility: Novartis Investigative Site
city: Kyev
country: Ukraine
facility: Novartis Investigative Site
city: Lugansk
country: Ukraine
facility: Novartis Investigative Site
city: Odesa
country: Ukraine
facility: Novartis Investigative Site
city: Truro
country: United Kingdom
facility: Novartis Investigative Site
state: Cornwall
city: Durham
country: United Kingdom
facility: Novartis Investigative Site
state: County Durham
city: Torquay
country: United Kingdom
facility: Novartis Investigative Site
state: Devon,
city: Bolton
country: United Kingdom
facility: Novartis Investigative Site
state: England
city: Solihull
country: United Kingdom
facility: Novartis Investigative Site
state: England
city: Southampton
country: United Kingdom
facility: Novartis Investigative Site
state: England
city: Wakefield
country: United Kingdom
facility: Novartis Investigative Site
state: England
city: Belfast
country: United Kingdom
facility: Novartis Investigative Site
state: Essex
city: Romford
country: United Kingdom
facility: Novartis Investigative Site
state: Essex
city: Cheltenham
country: United Kingdom
facility: Novartis Investigative Site
state: Gloucestershire
city: Blackburn
country: United Kingdom
facility: Novartis Investigative Site
state: Lancashire
city: Hull
country: United Kingdom
facility: Novartis Investigative Site
state: Lancashire
city: Leicester
country: United Kingdom
facility: Novartis Investigative Site
state: Lancashire
city: Coventry
country: United Kingdom
facility: Novartis Investigative Site
state: London
city: Derby
country: United Kingdom
facility: Novartis Investigative Site
state: London
city: Leytonstone
country: United Kingdom
facility: Novartis Investigative Site
state: London
city: Oxford
country: United Kingdom
facility: Novartis Investigative Site
state: Oxfordshire
city: Sheffield
country: United Kingdom
facility: Novartis Investigative Site
state: South Yorkshire
city: Stoke-on-Trent
country: United Kingdom
facility: Novartis Investigative Site
state: Staffordshire
city: Frimley
country: United Kingdom
facility: Novartis Investigative Site
state: Surrey
city: Guildford
country: United Kingdom
facility: Novartis Investigative Site
state: Surrey
city: Worcester
country: United Kingdom
facility: Novartis Investigative Site
state: UK
city: Bradford
country: United Kingdom
facility: Novartis Investigative Site
state: West Yorkshire
city: Bedford
country: United Kingdom
facility: Novartis Investigative Site
city: Birmingham
country: United Kingdom
facility: Novartis Investigative Site
city: Bristol
country: United Kingdom
facility: Novartis Investigative Site
city: Cardiff
country: United Kingdom
facility: Novartis Investigative Site
city: Cheshire
country: United Kingdom
facility: Novartis Investigative Site
city: Colchester
country: United Kingdom
facility: Novartis Investigative Site
city: Inverness
country: United Kingdom
facility: Novartis Investigative Site
city: Kent
country: United Kingdom
facility: Novartis Investigative Site
city: Leeds
country: United Kingdom
facility: Novartis Investigative Site
city: Liverpool
country: United Kingdom
facility: Novartis Investigative Site
city: London
country: United Kingdom
facility: Novartis Investigative Site
city: London
country: United Kingdom
facility: Novartis Investigative Site
city: London
country: United Kingdom
facility: Novartis Investigative Site
city: London
country: United Kingdom
facility: Novartis Investigative Site
city: Maidstone
country: United Kingdom
facility: Novartis Investigative Site
city: Manchester
country: United Kingdom
facility: Novartis Investigative Site
city: Merseyside
country: United Kingdom
facility: Novartis Investigative Site
city: Merseyside
country: United Kingdom
facility: Novartis Investigative Site
city: Middlesborough
country: United Kingdom
facility: Novartis Investigative Site
city: Newport
country: United Kingdom
facility: Novartis Investigative Site
city: Portsmouth
country: United Kingdom
facility: Novartis Investigative Site
city: Southend
country: United Kingdom
facility: Novartis Investigative Site
city: Sunderland
country: United Kingdom
facility: Novartis Investigative Site
city: Uxbridge
country: United Kingdom
facility: Novartis Investigative Site
city: Wolverhampton
country: United Kingdom
facility: Novartis Investigative Site
city: York
country: United Kingdom
facility: Novartis Investigative Site
city: Porlamar Local 02
country: Venezuela
facility: Novartis Investigative Site
state: Isla Margarita
city: Caracas, Piso 6, Ofic. 607
country: Venezuela
facility: Novartis Investigative Site
city: Caracas
country: Venezuela
facility: Novartis Investigative Site
city: Santa Paula
country: Venezuela
facility: Novartis Investigative Site
city: Torre Venezuela, Piso 1
country: Venezuela
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Holz FG, Minnella AM, Tuli R, Yoganathan P, Parikh S, Hamilton R; LUMINOUS study group. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study. PLoS One. 2020 Dec 30;15(12):e0244183. doi: 10.1371/journal.pone.0244183. eCollection 2020.
citation: Leys AM, Ramboer E, Favreau M, Denhaerynck K, MacDonald K, Abraham I, Brie H. Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study. Clin Ophthalmol. 2020 Jun 2;14:1473-1481. doi: 10.2147/OPTH.S242547. eCollection 2020.
citation: Pearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, Creuzot-Garcher C, Spital G, Sakamoto T, Dunger-Baldauf C, McAllister IL; all the LUMINOUS study investigators. Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study. PLoS One. 2020 Jun 18;15(6):e0234739. doi: 10.1371/journal.pone.0234739. eCollection 2020.
citation: Mitchell P, Sheidow TG, Farah ME, Mahmood S, Minnella AM, Eter N, Eldem B, Al-Dhibi H, Macfadden W, Parikh S, Dunger-Baldauf C, Mahgoub MM, Schmidt-Erfurth U; LUMINOUS study investigators. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naive patients with diabetic macular edema: Results from the real-world global LUMINOUS study. PLoS One. 2020 Jun 3;15(6):e0233595. doi: 10.1371/journal.pone.0233595. eCollection 2020.
citation: Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Mones J, Richard G, Bandello F; European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014 Sep;98(9):1144-67. doi: 10.1136/bjophthalmol-2014-305702.